Supporting innovation in Australia with genOway’s solutions
Australia has a vibrant and rapidly evolving life sciences ecosystem, with biotech companies, pharmaceutical leaders, and academic institutes driving innovation across oncology, immunology, rare diseases, and other critical therapeutic areas.
However, drug development remains highly challenging: around 90% of drug candidates fail in clinical trials, most often due to a lack of predictive power in preclinical models. Improving translational relevance has therefore become a key priority for the industry.
GenOway Australia was established to directly support this need within the Australian ecosystem. We provide local access to genOway’s validated catalogue of genetically engineered preclinical models, as well as advanced custom model generation and integrated preclinical services. Our presence in Australia enables faster collaboration, closer scientific support, and solutions adapted to local research priorities and timelines.
In addition, genOway Australia streamlines access to high-quality models sourced from certified professional breeders, with coordinated logistics and reliable door-to-door delivery across the country. This ensures Australian research teams benefit from consistent model quality, reduced lead times, and seamless integration into their preclinical programs—helping to improve predictability and ultimately reduce the risk of late-stage clinical failure.
